{"id":2787,"date":"2026-08-30T11:00:00","date_gmt":"2026-08-30T15:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2787"},"modified":"2026-08-31T19:40:50","modified_gmt":"2026-08-31T23:40:50","slug":"fda-expands-stelara-to-pediatric-ulcerative-colitis","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2787","title":{"rendered":"FDA Expands Stelara to Pediatric Ulcerative Colitis"},"content":{"rendered":"

Company:<\/strong> Janssen Biotech (Johnson & Johnson) · Drug:<\/strong> Stelara (Ustekinumab) · Indication:<\/strong> Pediatric Ulcerative Colitis, Age 2+ · Regulatory Action:<\/strong> FDA Label Expansion · Date:<\/strong> August 28, 2026<\/p>\n

\"20260830_Janssen_Stelara_Therapeutic_Indications\"<\/p>\n

Summary<\/h4>\n

FDA approved Janssen’s Stelara, ustekinumab, for moderately to severely active ulcerative colitis in children aged two years and older. The agency’s support combined established adult ulcerative-colitis evidence, pediatric Crohn’s-disease pharmacokinetic and safety data, and a 52-week study in 112 pediatric ulcerative-colitis participants aged three to 17. Following an April 2026 pediatric Crohn’s-disease approval, Stelara is now the first non-TNF-targeting therapeutic monoclonal antibody approved across both principal forms of pediatric inflammatory bowel disease, though FDA’s summary does not disclose comparative efficacy or a full numerical benefit-risk profile.<\/p>\n

What Happened<\/h4>\n

The new indication covers children aged two years and older with moderately to severely active ulcerative colitis. Ustekinumab blocks the shared p40 subunit of interleukin-12 and interleukin-23, reducing signaling involved in chronic intestinal inflammation. FDA granted the indication to Janssen Biotech and noted orphan-drug designation. The supporting evidence used a mixed package rather than a single stand-alone pediatric randomized efficacy dataset: adult controlled ulcerative-colitis studies, pediatric Crohn’s-disease exposure and safety evidence, and additional 52-week pediatric ulcerative-colitis efficacy, safety and pharmacokinetic data. The registered UNIFI Jr study is Phase III, includes open-label intravenous induction and randomized double-blind subcutaneous maintenance, and is listed as completed, though public registry results were not posted in the source snapshot.<\/p>\n

Deep Analysis<\/h4>\n

Pediatric ulcerative colitis can be aggressive, and patients may need alternatives when corticosteroids, immunomodulators or anti-TNF agents are ineffective, poorly tolerated or unsuitable; a biologic with a distinct IL-12\/23 mechanism expands sequencing flexibility, and approval from age two broadens reach. The public FDA summary, however, does not provide remission rates, subgroup outcomes, dose-exposure relationships or direct comparison with anti-TNF, vedolizumab or other advanced therapies. The approval may primarily extend a mature franchise into a smaller pediatric population rather than reset the IBD treatment hierarchy; extrapolation from adult efficacy and related pediatric disease data is scientifically and regulatorily reasonable, but it increases dependence on assumptions about pediatric comparability, and without head-to-head data or long-term growth and development outcomes, competitive displacement should not be inferred.<\/p>\n

Company and Product Background<\/h4>\n

Janssen Biotech is part of Johnson & Johnson Innovative Medicine. Ustekinumab is a fully human monoclonal antibody directed against the p40 protein subunit shared by interleukin-12 and interleukin-23; by preventing receptor engagement, it reduces downstream T-helper-1 and T-helper-17 inflammatory signaling, a mechanism distinct from TNF blockade. Ulcerative colitis is a chronic inflammatory disease of the colonic mucosa that causes bleeding, diarrhea, urgency and systemic complications; childhood-onset disease can impair growth, nutrition, schooling and quality of life and may require prolonged immunosuppression or surgery.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
New Indication<\/td>\nModerately to severely active ulcerative colitis, ages 2 and older<\/td>\n<\/tr>\n
Evidence Package<\/td>\nAdult UC data, pediatric Crohn’s PK\/safety data, 52-week study in 112 pediatric UC patients<\/td>\n<\/tr>\n
Franchise Context<\/td>\nFirst non-TNF monoclonal antibody approved across both major pediatric IBD forms<\/td>\n<\/tr>\n
Disclosed Numbers<\/td>\nNone; FDA summary omits remission rates and comparative data<\/td>\n<\/tr>\n
Signal Type<\/td>\nRegulatory label expansion, lifecycle extension<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> A biologic with a distinct IL-12\/23 mechanism, now approved from age two and across both principal pediatric IBD forms, gives physicians practical sequencing flexibility for children who cannot continue anti-TNF therapy.<\/p>\n

Bear case:<\/strong> The public record lacks remission rates, subgroup outcomes and comparative data against anti-TNF or vedolizumab, so the approval should be read as a lifecycle extension rather than evidence of preferred positioning in the pediatric IBD treatment hierarchy.<\/p>\n

InSilens Take<\/h4>\n

The approval adds a validated mechanism and practical sequencing option for children with moderate-to-severe ulcerative colitis, a real clinical gain particularly for patients who cannot continue anti-TNF therapy. But it should be read as an evidence-supported label expansion, not proof that Stelara is the preferred pediatric biologic; the public record is still too sparse on numerical efficacy, age strata and comparative performance to infer broad displacement.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 3\/5 · Direction:<\/strong> Positive · Confidence:<\/strong> High on facts, Moderate on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

FDA approved Janssen’s Stelara, ustekinumab, for moderately to severely active ulcerative colitis in children aged two years and older. The agency’s support combined established adult ulcerative-colitis evidence, pediatric Crohn’s-disease pharmacokinetic and safety data, and…<\/p>\n","protected":false},"author":1,"featured_media":2795,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[475,477,476],"class_list":["post-2787","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-stelara","tag-ulcerative-colitis","tag-ustekinumab"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2787"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2787\/revisions"}],"predecessor-version":[{"id":2803,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2787\/revisions\/2803"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2795"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}